Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P. Vertex Pharmaceuticals Inc Transaction History
Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P.
- $653 Million
- Q3 2024
A detailed history of Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P. holds 1,973 shares of VRTX stock, worth $918,826. This represents 0.14% of its overall portfolio holdings.
Number of Shares
1,973
Previous 1,825
8.11%
Holding current value
$918,826
Previous $855,000
7.25%
% of portfolio
0.14%
Previous 0.18%
Shares
5 transactions
Others Institutions Holding VRTX
# of Institutions
1,722Shares Held
222MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.5 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.8 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.93 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.5 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.19 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $120B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...